Covalent Modifiers

OCTOBER 21, 2023

Seong Ho Hong , Akane Osa , Ingrid E Wertz , Daniel Nomura bioRxiv 2023.10.20.563371; doi: [link] Targeted protein degradation with Proteolysis Targeting Chimeras (PROTACs) is a powerful therapeutic modality for eliminating disease-causing proteins through targeted ubiquitination and proteasome-mediated degradation. Most PROTACs have exploited substrate receptors of Cullin-RING E3 ubiquitin ligases such as cereblon and VHL.

Targeted Protein Degradation 65

Targeted Protein Degradation Disease 65

Drug Patent Watch

OCTOBER 21, 2023

Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for MYLAN drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

KIF1A

OCTOBER 21, 2023

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. KIF1A-Related Research Phosphatidylinositol 3,5-bisphosphate facilitates axonal vesicle transport and presynapse assembly Imagine a transport company that sends truck shipments of bricks to a construction company; the

Regulations 105

Regulations Doctors Packaging Disease 105

Drug Patent Watch

OCTOBER 21, 2023

Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for Sandoz drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

OCTOBER 21, 2023

This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drugs 59